JP2024537775A5 - - Google Patents

Info

Publication number
JP2024537775A5
JP2024537775A5 JP2024519288A JP2024519288A JP2024537775A5 JP 2024537775 A5 JP2024537775 A5 JP 2024537775A5 JP 2024519288 A JP2024519288 A JP 2024519288A JP 2024519288 A JP2024519288 A JP 2024519288A JP 2024537775 A5 JP2024537775 A5 JP 2024537775A5
Authority
JP
Japan
Prior art keywords
seq
promoter
construct
aav
kcnq4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024519288A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537775A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/077222 external-priority patent/WO2023056329A1/en
Publication of JP2024537775A publication Critical patent/JP2024537775A/ja
Publication of JP2024537775A5 publication Critical patent/JP2024537775A5/ja
Pending legal-status Critical Current

Links

JP2024519288A 2021-09-30 2022-09-29 Kcnq4関連難聴を治療するための組成物及び方法 Pending JP2024537775A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163250857P 2021-09-30 2021-09-30
US63/250,857 2021-09-30
US202263305740P 2022-02-02 2022-02-02
US63/305,740 2022-02-02
US202263309061P 2022-02-11 2022-02-11
US63/309,061 2022-02-11
PCT/US2022/077222 WO2023056329A1 (en) 2021-09-30 2022-09-29 Compositions and methods for treating kcnq4-associated hearing loss

Publications (2)

Publication Number Publication Date
JP2024537775A JP2024537775A (ja) 2024-10-16
JP2024537775A5 true JP2024537775A5 (https=) 2025-10-14

Family

ID=84358215

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024519288A Pending JP2024537775A (ja) 2021-09-30 2022-09-29 Kcnq4関連難聴を治療するための組成物及び方法

Country Status (15)

Country Link
US (1) US20250288692A1 (https=)
EP (1) EP4408872A1 (https=)
JP (1) JP2024537775A (https=)
KR (1) KR20240067112A (https=)
AU (1) AU2022356427A1 (https=)
CA (1) CA3233097A1 (https=)
CO (1) CO2024003631A2 (https=)
CR (1) CR20240169A (https=)
DO (1) DOP2024000054A (https=)
EC (1) ECSP24032712A (https=)
IL (1) IL311572A (https=)
JO (1) JOP20240061A1 (https=)
MX (1) MX2024003778A (https=)
PE (1) PE20241065A1 (https=)
WO (1) WO2023056329A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4695406A1 (en) * 2023-04-13 2026-02-18 F. Hoffmann-La Roche AG Improved recombinant polyadenylation signal sequences and use thereof

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5130300A (en) 1986-03-07 1992-07-14 Monsanto Company Method for enhancing growth of mammary parenchyma
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
EP0366685B1 (en) 1987-06-24 1994-10-19 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5252334A (en) 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
CA2029273A1 (en) 1989-12-04 1991-06-05 Christine L. Brakel Modified nucleotide compounds
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5457191A (en) 1990-01-11 1995-10-10 Isis Pharmaceuticals, Inc. 3-deazapurines
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JPH0874B2 (ja) 1990-07-27 1996-01-10 アイシス・ファーマシューティカルス・インコーポレーテッド 遺伝子発現を検出および変調するヌクレアーゼ耐性、ピリミジン修飾オリゴヌクレオチド
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
EP0538194B1 (de) 1991-10-17 1997-06-04 Novartis AG Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US6015886A (en) 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5697899A (en) 1995-02-07 1997-12-16 Gensia Feedback controlled drug delivery system
WO1996027606A1 (en) 1995-03-06 1996-09-12 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US5656016A (en) 1996-03-18 1997-08-12 Abbott Laboratories Sonophoretic drug delivery system
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US5783208A (en) 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5779708A (en) 1996-08-15 1998-07-14 Cyberdent, Inc. Intraosseous drug delivery device and method
EP0931158A1 (en) 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6639062B2 (en) 1997-02-14 2003-10-28 Isis Pharmaceuticals, Inc. Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
US6548286B1 (en) 1997-04-14 2003-04-15 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant AAV product
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6528640B1 (en) 1997-11-05 2003-03-04 Ribozyme Pharmaceuticals, Incorporated Synthetic ribonucleic acids with RNAse activity
US6617438B1 (en) 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US7045610B2 (en) 1998-04-03 2006-05-16 Epoch Biosciences, Inc. Modified oligonucleotides for mismatch discrimination
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
AU2092700A (en) * 1999-01-26 2000-08-18 Neurosearch A/S Novel potassium channels and genes encoding these potassium channels
US6147200A (en) 1999-08-19 2000-11-14 Isis Pharmaceuticals, Inc. 2'-O-acetamido modified monomers and oligomers
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US6492171B2 (en) 2000-05-16 2002-12-10 Isis Pharmaceuticals, Inc. Antisense modulation of TERT expression
US7201898B2 (en) 2000-06-01 2007-04-10 The University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
JP4608210B2 (ja) 2001-05-31 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド キメラアルファウイルスレプリコン粒子
ES2330202T5 (es) 2001-09-06 2014-01-20 Alphavax, Inc. Sistemas vectores basados en replicones de alfavirus
MX359371B (es) 2001-11-13 2018-09-25 Univ Pennsylvania Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
PT1453547T (pt) 2001-12-17 2016-12-28 Univ Pennsylvania Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
AU2003274397A1 (en) 2002-06-05 2003-12-22 University Of Florida Production of pseudotyped recombinant aav virions
EP1661905B9 (en) 2003-08-28 2012-12-19 IMANISHI, Takeshi Novel artificial nucleic acids of n-o bond crosslinkage type
EP2345731B1 (en) 2003-09-30 2015-10-21 The Trustees of the University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
CA2553676A1 (en) 2004-01-28 2005-08-11 Research Development Foundation Human soluble neuropilin-1 primary polyadenylation signal and uses thereof
WO2006012414A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Novel polyadenylation signal for use in expression vectors
ES2525067T3 (es) 2005-04-07 2014-12-17 The Trustees Of The University Of Pennsylvania Método de incremento de la función de un vector de AAV
WO2007090071A2 (en) 2006-01-27 2007-08-09 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
AU2007249349B2 (en) 2006-05-11 2012-03-08 Isis Pharmaceuticals, Inc. 5'-Modified bicyclic nucleic acid analogs
US8889394B2 (en) 2009-09-07 2014-11-18 Empire Technology Development Llc Multiple domain proteins
JP2013541510A (ja) 2010-08-31 2013-11-14 メルク・シャープ・エンド・ドーム・コーポレイション 新規の単一の化学物質、およびオリゴヌクレオチドの送達方法
AU2013240248B2 (en) 2012-03-26 2018-12-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Delivery of packaged RNA to mammalian cells
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
ES2745769T3 (es) 2014-03-10 2020-03-03 Editas Medicine Inc Procedimientos y composiciones relacionados con CRISPR/CAS para tratar la amaurosis congénita de Leber 10 (LCA10)
EP4464338A3 (en) 2014-11-07 2025-02-12 Editas Medicine, Inc. Systems for improving crispr/cas-mediated genome-editing
US10201455B2 (en) 2016-06-22 2019-02-12 The Charles Stark Draper Laboratory, Inc. System for inner ear drug delivery via trans-round window membrane injection
EP3661523A4 (en) 2017-08-03 2021-08-04 University of Iowa Research Foundation TREATMENT METHODS FOR GENETIC HEARING LOSS
WO2019084145A1 (en) 2017-10-25 2019-05-02 The Charles Stark Draper Laboratory Inc. APPARATUS AND METHOD FOR DRUG DELIVERY ACROSS THE ROUND WINDOW MEMBRANE

Similar Documents

Publication Publication Date Title
Sacheli et al. Gene transfer in inner ear cells: a challenging race
CN114929205B (zh) 包括末端封闭式dna和可切割脂质的脂质纳米颗粒组合物及其使用方法
US20230242910A1 (en) Methods and compositions relating to engineered guide systems for adenosine deaminase acting on rna editing
CN105579465B (zh) 用于基因转移到细胞、器官和组织中的变异aav和组合物、方法及用途
JP2022008560A (ja) 無カプシドaavベクター、組成物ならびにベクター製造および遺伝子運搬のための方法
EP3796893A1 (en) Delivery of dna
CN111132699A (zh) 修饰的封闭端dna(cedna)
BR112020013319A2 (pt) vetores de dna de extremidade fechada obteníveis a partir de síntese livre de células e processo para obter vetores de cedna
CN109154002B (zh) 用于治疗显性视网膜色素变性的aav载体
JP2023526053A5 (https=)
CN113316640A (zh) 包含对称的被修饰的反向末端重复序列的被修饰的封闭端dna(cedna)
CN117858891A (zh) 用于基因疗法的经修饰aav衣壳及其方法
AU2020367437B2 (en) Gene therapy for Alzheimer's disease
CN113874513A (zh) 非病毒dna载体及其用于表达fviii治疗剂的用途
US12442017B2 (en) Microglial selective gene expression vector
JP2024521052A5 (https=)
JP2024537775A5 (https=)
US20230313223A1 (en) Methods for modulating level of expression from gene therapy expression cassette
JP2024537796A5 (https=)
CN118489008A (zh) 封闭端dna载体的可扩展且高纯度无细胞合成
WO2022221397A2 (en) Plasmids and methods of production of adeno-associated viruses
CN120322449A (zh) Atp7b基因疗法
WO2024091495A1 (en) Compositions and methods for treating retinitis pigmentosa
JP2025534556A (ja) 網膜色素変性症を治療するための組成物及び方法
TW202603169A (zh) Acta1表現控制元件